Hologic(US:HOLX)2025-05-01 22:47Company Overview - Hologic operates across three segments: Diagnostics (44%), Breast and Skeletal Health (40%), and Surgical (16%) [14] - The company's revenue is primarily driven by consumables (62%), followed by capital (19%) and service & other (19%) [14] - The US market accounts for 75% of Hologic's revenue, while international markets contribute 25% [14] Financial Performance and Growth - Hologic has demonstrated mid-single-digit total sales growth [17] - The company has achieved double-digit non-GAAP EPS growth [19] - Q2'25 revenue was $1,005.3 million, a decrease of 1.2% compared to Q2'24 [69, 71] - Hologic forecasts full year 2025 revenue between $4,050 million and $4,100 million, representing a 0.5% to 1.7% increase [74] - The company anticipates full year 2025 non-GAAP diluted EPS between $4.15 and $4.25, a 1.7% to 4.2% increase [74] Strategic Focus and International Expansion - Hologic aims to continue double-digit non-GAAP EPS growth, driven by mid-single-digit revenue growth, operating margin expansion, acquisitions, and buybacks [77] - International revenue has grown from $533 million in 2014 to $999 million in 2024 [51]